DSTP3086S: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 28 patients with CRPC showed that the recommended Phase II dose of IV DSTP3086S was 2.8 mg/kg given every 3 weeks. Dose-limiting toxicities (DLTs)...